Association of Myeloma in Patients of Chronic Kidney Disease; A Single Centered Study

Authors

  • Farzana Adnan Sheikh
  • Syed Tajammul Ali
  • Sidra Rashid
  • Mehwish Qamar
  • Khadijah Abid

DOI:

https://doi.org/10.51985/JBUMDC2022123

Keywords:

Chronic Kidney Disease, End Stage Renal Disease, Myeloma

Abstract

Objective: To evaluate the frequency along with socio-demographic factors and clinical features of myeloma in patients with chronic kidney disease (CKD) presenting at a tertiary care hospital in Karachi, Pakistan.

Study design and setting: It was a cross-sectional study conducted at the Department of Nephrology and Hematology, Liaquat National Hospital, Karachi, Pakistan from Jan 2022 to Jul 2022.

Methodology: Patients of age>18 years of either gender having chronic kidney disease were included in the study. Detailed data regarding socio-demographic factors, clinical features and presence of multiple myeloma was obtained. Myeloma was diagnosed in the patients using WHO criteria i.e. presence of M-protein in urine or serum, presence of clonal plasma cells in bone marrow, and related tissue or organ failure. Data was entered and analyzed using SPSS version 25.

Results: The median age of the patients with chronic kidney disease was 54 years and most of them were males (63%). Myeloma was detected in only 14 patients with CKD. The proportion of myeloma was similar across chronic kidney disease stages, and statistically there was no significant association between chronic kidney disease stages and myeloma with pvalue=0.08. There were no differences in hemoglobin, serum calcium, serum albumin, serum total protein, albumin/globulin (A/G) ratio, ESR, comorbid in patients with and without myeloma (p>0.05).

Conclusion: The frequency of myeloma among patients with chronic kidney disease was low.

References

Li S, Gong T, Kou C, Fu A, Bolanos R, Liu J. Clinical

Outcomes Associated With Chronic Kidney Disease in Elderly

Medicare Patients With Multiple Myeloma. Clin Lymphoma

Myeloma Leuk. 2021;21(6):401-12.e24.'10.1016/j.clml.

01.015:'10.1016/j.clml.2021.01.015.

Understanding Myeloma, Cancer Council Australia ©2018.

Last medical review of source booklet: September 2018. .

Shi H, Chen Z, Xie J, Chen N. The Prevalence and

Management of Multiple Myeloma-Induced Kidney Disease

in China. Kidney Dis (Basel). 2016;1(4):235-40.'10.1159/

:'10.1159/000443492.

Vakiti A, Padala SA, Mewawalla P. Myeloma Kidney. [Updated

Jun 27]. In: StatPearls [Internet]. Treasure Island (FL):

StatPearls Publishing; 2022 Jan-. Available from: https://

www.ncbi.nlm.nih.gov/books/NBK499952/.

Basharat S, Batool Z, Ali N. Clinical profile of multiple

myeloma in a tertiary care hospital of Peshawar, Pakistan.

Khyber Med Univ J 2019;11(3):152-5. DOI: 10.35845/ KMUJ.

18790.

WHO. GLOBOCAN 2020: International Agency for Research

on Cancer; 2021 [Available from: https://gco.iarc.fr/today/

data/factsheets/populations/586-pakistan-fact-sheets.pdf.

Katagiri D, Noiri E, Hinoshita F. Multiple myeloma and

kidney disease. ScientificWorldJournal. 2013;2013:487285.'

1155/2013/487285:'10.1155/2013/487285.

Owoyemi I, Sethi S, Leung N. Kidney Injury in Multiple

Myeloma: A Kidney Biopsy Teaching Case. Kidney Medicine.

;3(2):303-6.'https://doi.org/10.1016/ j.xkme.2020.1

013:'https://doi.org/10.1016/j.xkme.2020.10.013.

Rana R, Cockwell P, Drayson M, Cook M, Pratt G, Cairns

DA, et al. Renal outcome in patients with newly diagnosed

multiple myeloma: results from the UK NCRI Myeloma XI

trial. Blood Adv. 2020;4(22):5836-45.'10.1182/bloodadvances.

:'10.1182/bloodadvances.2020002872.

Mok Y, Matsushita K, Ballew SH, Sang Y, Jung KJ, Lee S,

et al. Kidney Function, Proteinuria, and Cancer Incidence:

The Korean Heart Study. Am J Kidney Dis. 2017;70(4):512-

'10.1053/j.ajkd.2017.03.018:'10.1053/j.ajkd.2017.03.018.

Mok Y, Matsushita K, Sang Y, Ballew SH, Grams M, Shin

SY, et al. Association of Kidney Disease Measures with CauseSpecific Mortality: The Korean Heart Study. PLoS One.

;11(4):e0153429.'10.1371/journal.pone.0153429:'10.1

/journal.pone.0153429.

Mian HS, Fiala MA, Sanchez L, Vij R, Wildes TM. Renal

failure among multiple myeloma patients utilizing carfilzomib

and associated factors in the "real world". Ann Hematol.

;100(5):1261-6.'10.1007/s00277-021-04420-3:'10.

/s00277-021-04420-3.

Sharma R, Jain A, Jandial A, Lad D, Khadwal A, Prakash G,

et al. Lack of Renal Recovery Predicts Poor Survival in

Patients of Multiple Myeloma With Renal Impairment. Clinical

Lymphoma Myeloma and Leukemia. 2022;22(8):626-

'https://doi.org/10.1016/j.clml.2022.04.013:'https://doi.or

g/10.1016/j.clml.2022.04.013.

Rosner MH, Jhaveri KD, McMahon BA, Perazella MA.

Onconephrology: The intersections between the kidney and

cancer. CA: A Cancer Journal for Clinicians. 2021;71(1):47-

'https://doi.org/10.3322/caac.21636:'https://doi.org/10.33

/caac.21636.

Gulla A, Anderson KC. Multiple myeloma: the (r)evolution

of current therapy and a glance into future. Haematologica.

;105(10):2358-67.'10.3324/haematol. 2020.247015

:'10.3324/haematol.2020.247015.

Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F,

et al. Multiple Myeloma Therapy: Emerging Trends and

Challenges. Cancers (Basel). 2022;14(17).'10.3390/

cancers14174082 :'10.3390/cancers14174082.

Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure

multiple myeloma. Cancer Treat Rev. 2021;100:102284.'

1016/j.ctrv.2021.102284:'10.1016/j.ctrv.2021.102284.

Kint N, Vlayen S, Delforge M. The treatment of multiple

myeloma in an era of precision medicine. Expert Review of

Precision Medicine and Drug Development. 2019;4(3):153-

Soleymanian T, Soleimani A, Musavi A, Mojtahedi K, Hamid

G. Outcome of patients with multiple myeloma and renal

failure on novel regimens. Saudi Journal of Kidney Diseases

and Transplantation. 2016;27(2):335-40.'10.4103/1319-

178557:'10.4103/1319-2442.178557.

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ,

Dispenzieri A, et al. Review of 1027 patients with newly

diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-

'10.4065/78.1.21:'10.4065/78.1.21.

Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia

Sanz R, Powles R, et al. International Myeloma Working

Group recommendations for global myeloma care. Leukemia.

;28(5):981-92.'10.1038/leu.2013. 293:'10. 1038/ leu.2

293.

Devi A, Sharma T, Singh Y, Sonia H. Clinicopathological

profile of patients with non-hodgkin's lymphoma at a

regional cancer center in Northeast India. Journal of the

Scientific Society. 2017;44(3):140-4.'10.4103/jss.JSS_42_17

:'10.4103/jss.JSS_42_17.

Shaheen H, Ghanghroo I, Malik I. Clinicopathological features

and management of Pakistani patients with multiple myeloma.

J Pak Med Assoc. 1999;49(10):233-7.

Kaur P, Shah BS, Baja P. Multiple myeloma: a clinical and

pathological profile. Gulf J Oncolog. 2014;1(16):14-20.

Downloads

Published

2023-10-23

How to Cite

Sheikh, F. A., Ali, S. T. ., Rashid, S. ., Qamar, M. ., & Abid, K. . (2023). Association of Myeloma in Patients of Chronic Kidney Disease; A Single Centered Study. Journal of Bahria University Medical and Dental College, 13(04), 261–6. https://doi.org/10.51985/JBUMDC2022123

Issue

Vol. 13 No. 04 (2023): VOLUME 13 ISSUE 04

Section

Original Articles

License

Copyright (c) 2023 Farzana Adnan Sheikh, Syed Tajammul Ali, Sidra Rashid, Mehwish Qamar, Khadijah Abid

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0